Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02211209
Recruitment Status : Completed
First Posted : August 7, 2014
Last Update Posted : December 20, 2019
Sponsor:
Collaborator:
Akcea Therapeutics
Information provided by (Responsible Party):
Ionis Pharmaceuticals, Inc.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of volanesorsen given for 52 weeks in participants with Familial Chylomicronemia Syndrome

Condition or disease Intervention/treatment Phase
Familial Chylomicronemia Syndrome Drug: Volanesorsen Drug: Placebo Phase 3

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 67 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS)
Actual Study Start Date : December 2014
Actual Primary Completion Date : December 19, 2016
Actual Study Completion Date : March 28, 2017

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Placebo Comparator: Placebo
Volanesorsen-matching placebo administered subcutaneously once-weekly for 52 weeks.
 Drug: Placebo
Experimental: Volanesorsen
Volanesorsen 300 mg administered subcutaneously once-weekly for 52 weeks.
 Drug: Volanesorsen
Other Names:
  • ISIS 304801
  • ApoC-III
  • Approach
  • IONIS-APOCIIIRx


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Efficacy of ISIS-APOCIIIRx as measured by the percent change in fasting triglycerides from baseline [ Time Frame: 13 Weeks ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • History of chylomicronemia
  • A diagnosis of Familial Chylomicronemia Syndrome (Type 1 Hyperlipoproteinemia)
  • Fasting triglycerides (TG) ≥ 750 mg/dL (8.4 mmol/L) at Screening

Exclusion Criteria:

  • Diabetes mellitus if newly diagnosed or if HbA1c ≥ 9.0%
  • Other types of severe hypertriglyceridemia
  • Active pancreatitis within 4 weeks of screening
  • Acute Coronary Syndrome within 6 months of screening
  • Major surgery within 3 months of screening
  • Treatment with Glybera therapy within 2 years of screening
  • Previous treatment with IONIS-APOCIIIRx
  • Have any other conditions in the opinion of the investigator which could interfere with the participant participating in or completing the study
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02211209


Locations
Layout table for location information
United States, California
IONIS Investigative Site
Encinitas, California, United States, 92024
IONIS Investigative Site
San Francisco, California, United States, 94143
United States, Kansas
IONIS Investigative Site
Kansas City, Kansas, United States, 66214
United States, Massachusetts
IONIS Investigative Site
Boston, Massachusetts, United States, 02114
United States, New York
IONIS Investigative Site
New York, New York, United States, 10016
United States, Oklahoma
IONIS Investigative Site
Oklahoma City, Oklahoma, United States, 73103
United States, Oregon
IONIS Investigative Site
Portland, Oregon, United States, 97239
United States, Pennsylvania
IONIS Investigative Site
Philadelphia, Pennsylvania, United States, 19104
United States, Texas
IONIS Investigative Site
Houston, Texas, United States, 77030
United States, Virginia
IONIS Investigative Site
Norfolk, Virginia, United States, 23510
United States, Washington
IONIS Investigative Site
Seattle, Washington, United States, 98104
Brazil
IONIS Investigative Site
Campinas, Brazil, 13059-740
IONIS Investigative Site
Sao Paulo, Brazil, 04039-030
IONIS Investigative Site
Sao Paulo, Brazil, 05403-000
Canada, British Columbia
IONIS Investigative Site
Vancouver, British Columbia, Canada, V6Z1Y6
Canada, Quebec
IONIS Investigative Site
Chicoutimi, Quebec, Canada, G7H 5H6
IONIS Investigative Site
Sainte-Foy, Quebec, Canada, G1V 4M6
France
IONIS Investigative Site
Marseille, France, 13385
IONIS Investigative Site
Nantes, France, 44093
IONIS Investigative Site
Paris, France, 75013
Germany
IONIS Investigative Site
Berlin, Germany, 13353
IONIS Investigative Site
Dresden, Germany, 01307
Hungary
IONIS Investigative Site
Szikszo, Hungary, 3800
Israel
IONIS Investigative Site
Safed, Israel, 13110
Italy
IONIS Investigative Site
Milan, Italy, 20162
IONIS Investigative Site
Palermo, Italy, 90127
IONIS Investigative Site
Rome, Italy, 00161
Netherlands
IONIS Investigative Site
Amsterdam, Netherlands, 1105 AZ
IONIS Investigative Site
Rotterdam, Netherlands, 3000
South Africa
IONIS Investigative Site
Cape Town, South Africa, 7925
Spain
IONIS Investigative Site
Zaragoza, Aragon, Spain, 50009
IONIS Investigative Site
La Coruna, Galicia, Spain, 15001
IONIS Investigative Site
Barcelona, Spain, 08036
IONIS Investigative Site
Madrid, Spain, 28007
IONIS Investigative Site
Malaga, Spain, 29010
IONIS Investigative Site
Sevilla, Spain, 41013
United Kingdom
IONIS Investigative Site
Birmingham, United Kingdom, B9 5SS
IONIS Investigative Site
Manchester, United Kingdom, M13 9WL
IONIS Investigative Site
Manchester, United Kingdom, M23 9LT
IONIS Investigative Site
Peterborough, United Kingdom, PE3 9GZ
Sponsors and Collaborators
Ionis Pharmaceuticals, Inc.
Akcea Therapeutics
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications of Results:
Witztum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR, Yang Q, Hughes SG, Geary RS, Arca M, Stroes ESG, Bergeron J, Soran H, Civeira F, Hemphill L, Tsimikas S, Blom DJ, O'Dea L, Bruckert E. Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. N Engl J Med. 2019 Aug 8;381(6):531-542. doi: 10.1056/NEJMoa1715944. + Collaborators/Trial investigators: Alvarez-Sala L, Averna M, Ballantyne C, Baum S, Corder C, Diaz Diaz J, DuFour R, Dunbar R, Francis G, Gavish D , Goldberg I, Issa B, Izar M, Jones A, Julius A, Kane J, Krempf M, Lovell C, Martin S, Moriarty O, Muniz O, Neely R, Osamah H, Pauker Z, Quigley J, Rados D , Roeters van Lenneo J, Rosenblit R, Santos R, Soran H, Stefanutti C, Steinhagen-Thiessen E, Subramanian S, Valdivielso P, Valero R.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Ionis Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT02211209    
Other Study ID Numbers: ISIS 304801-CS6
2014-002421-35 ( EudraCT Number )
First Posted: August 7, 2014    Key Record Dates
Last Update Posted: December 20, 2019
Last Verified: December 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hyperlipoproteinemia Type I
Syndrome
Disease
Pathologic Processes
Lipid Metabolism, Inborn Errors
Metabolism, Inborn Errors
 Genetic Diseases, Inborn
Hyperlipoproteinemias
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases